Suppliers / Yangtze River Pharmaceutical Group Jiangsu Haici Biological Pharmaceutical
Yangtze River Pharmaceutical Group Jiangsu Haici Biological Pharmaceutical
China 934 employees Updated 9 July 2026
Yangtze River Pharmaceutical Group Jiangsu Haici Biological Pharmaceutical is an API manufacturer based in China. It holds 25 active US drug master files across a filed portfolio of 25 molecules. Its filings concentrate with NPRA (MY), AEMPS (ES) and MINSA (CR). Its GMP standing is certified by EMA.
3
registered plants
2 with an FDA FEI number
16
filings
across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Sources: FDA Establishment Registration, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Registered plants
| Site | FDA FEI |
| Taizhou, China | Not on file |
| China, China | 3009173840 |
| China, China | 3030810525 |
What they file, and where
| Molecule | Regulators | Docs |
| Afatinib | US FDA | 1 |
| Aripiprazole | US FDA | 1 |
| Dexmedetomidine | US FDA | 1 |
| Dexrazoxane | US FDA | 1 |
| Diquafosol | US FDA | 1 |
| Doxofylline | US FDA | 1 |
| Edaravone | US FDA | 1 |
| Empagliflozin | US FDA | 1 |
| Esomeprazole | US FDA | 1 |
| Gemcitabine | US FDA | 1 |
Show all 25 molecules on file
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| NPRA (MY) | 10 | None |
| AEMPS (ES) | 3 | None |
| MINSA (CR) | 2 | None |
| ARCSA (EC) | 1 | None |
| EMA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Yangtze River Pharmaceutical Group Jiangsu Haici Biological Pharmaceutical comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates